Document is current
Any future updates will be listed below
-
Authors
Jean-Baptiste, Milenka
Itzler, Robbin
Prusty, Subhransu
Supina, Dylan
Martin, Mona L. https://orcid.org/0000-0001-6899-2139
-
Funding
Funding for this research was provided by:
CSL Behring (EVA-24984-00-001)
- License Information
-
More Information
Article History
Received: 13 January 2022
Accepted: 8 May 2022
First Online: 16 June 2022
Declarations
:
: Key opinion leaders (KOLs) were asked to share their expertise and experiences in open-ended interviews. Each KOL was approached with a description of the task (work for hire) and purpose. If they agreed, each signed a contract that included confidentiality clauses, a description of the work, and agreed compensation for sharing their time and expertise.
: Not applicable.
: MM and MJB are employed by Evidera, Inc., which received funding from CSL Behring Inc. to carry out this research. RI and SP are employed by CSL Behring, a pharmaceutical company active in the development of medications for rare diseases, including hereditary angioedema. DS was employed by CSL Behring at the time this study was conducted and is now employed by Jazz Pharmaceuticals Inc.
